European Journal of Rheumatology
Original Article

How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study

1.

Department of Rheumatology, Luton and Dunstable University Hospital NHS Foundation Trust, Luton, United Kingdom

Eur J Rheumatol 2022; 9: 100-103
DOI: 10.5152/eurjrheum.2021.21027
Read: 116 Downloads: 53 Published: 01 April 2022

Objective: Even though disease-modifying antirheumatic drugs (DMARDs) are well established in rou- tine clinical practice, longitudinal real-world data for their retention and tolerability are sparse, espe- cially in psoriatic arthritis (PsA) patients. Our objective was to describe the characteristics of our large PsA cohort including the comorbidities and evaluate real-world DMARD tolerability and discontinua- tion rates with reasons for stopping treatment.

Methods: We retrospectively interrogated the electronic, multipurpose, live setting database at our uni- versity hospital to identify 335 patients diagnosed with PsA who had received conventional DMARDs (cDMARDs) and/or biologic DMARDs (bDMARDs) between 1994 up to and including April 2019.

Results: In total, 170 (50.7%) patients had discontinued one or more cDMARDs prior with a mean dura- tion before discontinuation of 9.9 months. In contrast, only 28 (24.8%) patients had stopped a course of bDMARDs at some point. The mean duration before biologic therapy was discontinued was 18.2 months.

Conclusion: To our knowledge, this is the first dedicated retrospective review of a large real-world PsA cohort addressing drug survival and tolerability of DMARDs over a 20-year period. Our study shows that in reality, cDMARDs are not well tolerated. This should encourage review of international guid- ance allowing earlier employment of biologics in the treatment paradigm.

Cite this article as: Jawad II, Nisar MK. How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study. Eur J Rheumatol.2022;9(2):100-103.

Files
EISSN 2148-4279